Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494392 | 0.78 | CXCR2 (0.43) | CXCR2ALDH1A1L3MBTL1TDP1MEN1 | |
| SCHEMBL5494013 | 0.75 | RAB9A (0.60) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL5450296 | 0.71 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL3860316 | 0.68 | RAB9A (0.58) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL8133016 | 0.68 | HSP90AA1 (0.56) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL13752162 | 0.67 | RAB9A (0.70) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL811481 | 0.67 | ALDH1A1 (0.78) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL4152240 | 0.66 | RAB9A (0.51) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL30716878 | 0.66 | RAB9A (0.51) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL6359047 | 0.65 | RAB9A (0.58) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328319-B1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| US-7071193-B2 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | ASTRAZENECA AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20040102447-A1 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1328319-A1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | AstraZeneca AB (SE) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002032507-A1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | ASTRAZENECA AB (SE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102447-A1 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | CXCR3, CXCR2, CCR2 | RAB9A 1726/4885SMN1; SMN2 2343/4885NPC1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.